Latest news
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
Iconovo announces that the company will receive a grant of SEK 680,000 from Innowwide. The grant will be used to carry out a market study to introduce…
Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag
Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…
Press releases
May 22, 2023, 08:30
News
IR
English
Regulatory
MAR
Corporate Action
Other
May 22, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
May 11, 2023, 08:30
News
IR
English
Corporate Action
Other
May 11, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Apr 28, 2023, 09:51
News
IR
Swedish
Correction
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 28, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
mfn-cus-disclaimer
Apr 20, 2023, 10:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 14, 2023, 08:45
News
IR
Swedish
Corporate Action
Other
Apr 14, 2023, 08:45
News
IR
English
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 04, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2023, 10:01
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 16, 2023, 14:30
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Feb 10, 2023, 11:20
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 09, 2023, 15:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 08, 2023, 23:59
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 23:59
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
Feb 08, 2023, 17:32
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se